The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...

Scientists have built functional cancer-fighting immune cells directly inside living animals, skipping the expensive and time-consuming process of extracting a patient’s cells and engineering them in ...

By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Initiating Coverage We are initiating coverage of Estrella Immunopharma (NASDAQ: ESLA) with a valuation of $12.00 per share and a ...

Creative Biolabs today announced the upgrade of its next-generation drug discovery pipeline with integrated AI-driven ...

This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work. What major challenge of traditional CAR-T does the in vivo alleviate/address? In ...

CAR T-cell therapies are individualized treatments approved for multiple hematologic malignancies, with improved management of adverse effects over time. Access to CAR T-cell therapies is limited by ...

In a recent study published in Proceedings of the National Academy of Sciences, researchers engineered Chimeric Antigen Receptor (CAR) CD4 T cells, a technology originally revolutionized for cancer ...